A GameStop on Sixth Avenue in New York City (John Smith/Getty Images)

GameStop’s business is getting better. The stock is getting cheaper.

The cost of betting on hopes and dreams seems a lot lower when net income and operating income are turning higher.

6/17/25 3:15PM

If you look at it a certain way… GameStop is trading kind of cheap.

The embattled video game retailer turned collectibles company has a market cap of over $10 billion. But roughly half of that is tied to the company’s net cash and short-term investments — largely US Treasurys, but also recently adding bitcoin to that list.

How is the underlying business being valued?

Well, GameStop’s market value is about 1.7x its expected sales in 12 months’ time, which is at the lower end of its range since May 2024, when the return of Keith Gill, aka Roaring Kitty, fueled another meme mania for the stock.

Compare that to Broadcom, whose market cap (less net cash and short-term investments) is about 17x its 12-month forward expected sales. Of course, that reflects investors’ belief that the chip designer’s sales will grow over time, a sentiment that is not shared with respect to GameStop.

The company hasn’t grown annual revenues since 2021, and isn’t forecast to do so this year or the next. That being said, sales aren’t everything. GameStop’s expense control has been admirable, especially since Ryan Cohen took over as CEO, to the point that the firm has generated an operating profit over its last four quarters despite a shrinking top line, and is forecast to do so for the 12 months ending January 2026.

Couple that with the money it’s spinning off from its barbell investment strategy of Treasurys plus bitcoin (though the latter is down since its date of purchase), and you’ve got a stew going. That’s what the newly positive trend for net income suggests. At the very least, the cash pile and the operating performance have translated to a longer and wider runway for the firm than what prevailed from early 2021 through April 2024.

Or if you prefer another more commonly cited valuation measure, the ratio of GameStop’s enterprise value (that is, market value plus debt less cash and equivalents) to its trailing free cash flow has plunged, recently hitting its lowest levels since before the 2021 craze that inspired books and movies.

GameStop’s pivot to bitcoin has not been well received by the market. But ever since its rally in the second half of 2020, when the stock was a textbook value play, it’s been a name you can dream on.

And the cost of dreaming has gone down.

Luke Kawa

58m

Beyond Meat tumbles as CEO blames American society for its business struggles after issuing weak sales outlook

The CEO equivalent of flipping over the table when board game night isn’t going well.

Max Knoblauch & David Crowther & Luke Kawa17h

Nike craters after issuing weak revenue guidance

Sportswear kingpin Nike is tumbling on Wednesday morning after saying it doesn’t expect to grow sales this year.

On its fiscal Q3 earnings call, management said that revenue is expected to drop 2% to 4% in the current quarter, and that overall they “expect revenues to be down low-single-digits versus the prior year, with gains in North America offset by declines in Greater China.” That's a disappointment to analysts, who were anticipating 2% growth in Q4, and even more in the latter stages of the year, per Bloomberg.

Nike’s Q3 sales in China — where the company earns about 15% of its revenue — fell 7% to $1.62 billion. The company had issued weak guidance for this quarter considering continued softness in the region. That’s its seventh straight quarter of sales declines in the market. While this quarter’s was decline was less than feared, management warned that more pain is in the offing.

Nike’s turnaround effort “is complex work, and parts of it are taking longer than I'd like,” said CEO Elliott Hill.

Nike’s fiscal Q3 results (the three months ended February) were solid at the headline level:

Earnings of $0.35 per share, comfortably above the Wall Street consensus of $0.29 per share compiled by FactSet.
$11.28 billion in total revenue, roughly in line with the $11.26 billion estimate.

But the gloomy sales outlook has Wall Street analysts souring on the stock:

JPMorgan downgraded the shares to “neutral” from “overweight” and cut its price target to $52 from $86.
Citi reduced its target price to $53 from $65,
Stifel lowered its price target to $56 from $65,
Truist reduced its price target to $57 from $69, and
Barclays cut its target price to $67 from $73.

Nike shares are trading near decade lows this month, as tariffs continue to weigh on profits and shipping costs rise amid the war with Iran. As of Tuesday’s close, the stock was down 17% year to date.

Luke Kawa, Tasha Matsumoto

17h

Stocks end worst quarter since 2022 with best day since May

Optimism that the end of the war may be near sent stocks surging.

Max Knoblauch19h

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

Travel stocks are surging on Tuesday as oil prices fall following reports from Iranian state media that President Masoud Pezeshkian said the country has “the necessary will to end this war,” but would only do so with guarantees that “prevent the recurrence of aggression.”

The war has sent oil prices and refining margins surging this month, causing airlines and cruise lines to cut profit forecasts despite reported high demand.

Following Tuesday’s update, shares of the big four US airlines (Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines) all climbed, along with smaller rivals including JetBlue. US airlines have stopped fuel hedging in recent years, increasing their exposure to upward swings in oil prices.

Cruise stocks also rallied, with Carnival and Norwegian up more than 6% and Royal Caribbean up about 5%.

J. Edward Moreno21h

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times reported Tuesday.

The potential move was previously reported by The Wall Street Journal, and teased by Health Secretary Robert F. Kennedy Jr. on the “Joe Rogan Experience” podcast in late February.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

GameStop’s business is getting better. The stock is getting cheaper.

More Markets

Nike craters after issuing weak revenue guidance

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The peptide gold rush: How impending deregulation could supercharge a shadow industry

Latest Stories